|Tigatuzumab (CS-1008) is an investigational, humanized agonistic monoclonal antibody directed against human death receptor 5 (TNFRSF10B; a TNF family catalytic receptor for TRAIL), which is expressed on the surface of many types of cancer cells. DR5 contains an intracellular death domain and interacts with FADD (Fas-associated protein with death domain) to mediate apoptisis.
Peptide sequences and structural information for this antibody are available from its IMGT/mAb-DB record. Peptide sequences matching the heavy and light chain variable regions of tigatuzumab are claimed in patent WO2001083560 , but this does not provide an affinity value for the antibody vs. DR5. The antibodies described in the patent were tetsed for their ability to induce apoptosis in cells expressing DR5.